Subcutaneous Infusion of Levodopa-Carbidopa Beneficial for Parkinson Disease
THURSDAY, April 11, 2024 -- Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease, according to a study published online March 15 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2024 Category: Pharmaceuticals Source Type: news
Epstein-Barr and MS; When Lewy Pathology Starts; Alzheimer's Blood Test Assessed
(MedPage Today) -- Antibody response to anti-Epstein-Barr virus nuclear antigen 1 (EBNA-1) may be a risk factor for multiple sclerosis (MS), a small study suggested. (JAMA Neurology)
ND0612, a subcutaneous levodopa-carbidopa infusion for Parkinson... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 19, 2024 Category: Neurology Source Type: news
Blood, CSF Marker Detects Parkinsonian Disorders
(MedPage Today) -- A novel blood and cerebrospinal fluid (CSF) measure showed promise as a biomarker for Parkinsonian disorders.
CSF levels of DOPA decarboxylase (DDC) -- an enzyme that converts levodopa into dopamine -- accurately identified... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 21, 2023 Category: Neurology Source Type: news
LD/CD Infusion Improves & quot;ON & quot; Time, Outcomes in Parkinson's LD/CD Infusion Improves & quot;ON & quot; Time, Outcomes in Parkinson's
Offering levodopa/carbidopa as a 24-hour continuous subcutaneous infusion could help to improve treatment on times and motor experiences of daily living compared with oral preparations.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 8, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Hope in Progress: American Parkinson Disease Association Supports Researchers With $1.975 Million in New Funding
From understanding levodopa induced dyskinesias to exploring environmental risk factors of PD, APDA-funded researchers pursue cutting-edge studies NEW YORK, Sept. 7, 2023 /PRNewswire-PRWeb/ -- The American Parkinson Disease Association (APDA) has just awarded $1.975 million to support... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 7, 2023 Category: Pharmaceuticals Tags: FVT NPT Source Type: news
Probiotics Improve Nonmotor Symptoms of Parkinson's Probiotics Improve Nonmotor Symptoms of Parkinson's
A four-strain probiotic helped patients with Parkinson ' s disease and constipation reduce the delay in levodopa treatment effect and improve symptoms such as sleep and fatigue, in a randomized trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 30, 2023 Category: Gastroenterology Tags: Neurology & Neurosurgery News Source Type: news
Novel Levodopa Delivery System Promises Continuous Dosing Novel Levodopa Delivery System Promises Continuous Dosing
Called DopaFuse, the experimental device is designed to deliver the levodopa and carbidopa into the mouth through a micropump within a wearable retainer.MDedge News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 4, 2023 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
New Form of Levodopa Might Improve Parkinson's Care
New clinical trial data show an extended-release version of a Parkinson’s disease drug could provide more stable relief for patients with the movement disorder. (Source: WebMD Health)
Source: WebMD Health - April 27, 2023 Category: Consumer Health News Source Type: news
New Form of Levodopa Might Improve Parkinson's Care
WEDNESDAY, April 26, 2023 -- An extended-release version of a Parkinson’s disease drug could provide more stable relief for patients with the movement disorder, new clinical trial data show.
The new formulation of levodopa, called IPX203,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 26, 2023 Category: General Medicine Source Type: news
No Pills, No Surgery, No Electrodes for Parkinson's Disease?
(MedPage Today) -- BOSTON -- Several technologies for delivering levodopa-carbidopa in a more physiologically natural fashion than is possible with ordinary oral versions for Parkinson's disease took center stage here at neurology's leading scientific... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 26, 2023 Category: Neurology Source Type: news
Novel Continuous Infusion System Promising for Parkinson's Novel Continuous Infusion System Promising for Parkinson's
Continuous infusion strategies have long been sought as a method to preserve levodopa efficacy.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Effect of levodopa and environmental setting on gait and turning digital markers related to falls in people with Parkinson's disease - Shah VV, McNames J, Carlson-Kuhta P, Nutt JG, El-Gohary M, Sowalsky K, Mancini M, Horak FB.
BACKGROUND: It is unknown whether medication status (off and on levodopa) or laboratory versus home settings plays a role in discriminating fallers and non-fallers in people with Parkinson's disease (PD). OBJECTIVES: To investigate which specific d... (Source: SafetyLit)
Source: SafetyLit - February 28, 2023 Category: International Medicine & Public Health Tags: Environmental Issues, Climate, Geophysics Source Type: news
Neurons in Dish Learn to Play Pong; Levodopa and Early Parkinson's; Selma Blair's MS
(MedPage Today) -- In vitro human and mouse neurons learned to play the classic arcade game Pong in a dish coated with electrodes. Watch here. (Neuron)
Serum ocrelizumab (Ocrevus) concentration may be a good predictor of COVID vaccine response... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 18, 2022 Category: Neurology Source Type: news
Will Parkinson's Disease Therapy Move Past Carbidopa-Levodopa? Will Parkinson's Disease Therapy Move Past Carbidopa-Levodopa?
Kathrin LaFaver, MD, and Indu Subramanian, MD, discuss updates on Parkinson ' s disease, including highlights of the 2022 International Congress of Parkinson ' s Disease and Movement Disorders.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 13, 2022 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Results from a Phase III Clinical Trial for Subcutaneous Infusion of...
Continuous subcutaneous infusion (CSCI) of levodopa/carbidopa prodrugs, foslevodopa/foscarbidopa, improved time without dyskinesia in patients with advanced Parkinson’s disease (PD) according to a...(PRWeb September 15, 2022)Read the full story at https://www.prweb.com/releases/results_from_a_phase_iii_clinical_trial_for_subcutaneous_infusion_of_foslevodopa_foscarbidopa/prweb18891204.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 15, 2022 Category: Pharmaceuticals Source Type: news
